Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Liraglutide in the management of type 2 diabetes Wajcberg E; Amarah ADrug Des Devel Ther 2010[Oct]; 4 (ä): 279-90The pathophysiology of type 2 diabetes has been attributed to the classic triad of decreased insulin secretion, increased insulin resistance, and elevated hepatic glucose production. Research has shown additional mechanisms, including incretin deficiency or resistance in the gastrointestinal tract. Liraglutide is a modified form of human glucagon-like peptide-1. Liraglutide was obtained by substitution of lysine 34 for arginine near the NH2 terminus, and by addition of a C16 fatty acid at the varepsilon-amino group of lysine (at position 26) using a gamma-glutamic acid spacer. Liraglutide has demonstrated glucose-dependent insulin secretion, improvements in beta-cell function, deceleration of gastric emptying, and promotion of early satiety leading to weight loss. Liraglutide has the potential to acquire an important role, not only in the treatment of type 2 diabetes, but also in preservation of beta-cell function, weight loss, and prevention of chronic diabetic complications.|Animals[MESH]|Diabetes Mellitus, Type 2/*drug therapy/physiopathology[MESH]|Glucagon-Like Peptide 1/adverse effects/*analogs & derivatives/pharmacology/therapeutic use[MESH]|Humans[MESH]|Hypoglycemic Agents/adverse effects/pharmacology/*therapeutic use[MESH]|Insulin Secretion[MESH]|Insulin-Secreting Cells/metabolism[MESH]|Insulin/metabolism[MESH]|Liraglutide[MESH]|Weight Loss/drug effects[MESH] |
